The CALHM1 P86L Polymorphism is a Genetic Modifier of Age at Onset in Alzheimer's Disease: a Meta-Analysis Study
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
The only established genetic determinant of non-Mendelian forms of Alzheimer's disease (AD) is the ε4 allele of the apolipoprotein E gene (APOE). Recently, it has been reported that the P86L polymorphism of the calcium homeostasis modulator 1 gene (CALHM1) is associated with the risk of developing AD. In order to independently assess this association, we performed a meta-analysis of 7,873 AD cases and 13,274 controls of Caucasian origin (from a total of 24 centers in Belgium, Finland, France, Italy, Spain, Sweden, the UK, and the USA). Our results indicate that the CALHM1 P86L polymorphism is likely not a genetic determinant of AD but may modulate age of onset by interacting with the effect of the ε4 allele of the APOE gene.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
Self-citationSystematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database
Bertram, L., McQueen, M. B., Mullin, K., Blacker, D., & Tanzi, R. E. (2007) · Nature Genetics · doi:10.1038/ng1934 · Cited by 1,857 · cited 1×
“org) [7].”
Self-citationRole of Genes and Environments for Explaining Alzheimer Disease
Gatz, M., Reynolds, C. A., Fratiglioni, L., Johansson, B., Mortimer, J. A., Berg, S., Fiske, A., & Pedersen, N. L. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.2.168 · Cited by 1,798 · cited 2×
“This evidence is largely based on twin studies which have shown that the heritability of AD in general is high (between 60 and 80%) [3].”
BackgroundResultAmyloid, the presenilins and Alzheimer’s disease
Hardy, J. (1997) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)01030-2 · Cited by 1,370 · cited 1×
“Hereditary, earlyonset forms of AD have been linked to disease-causing mutations in three different genes: the amyloid-β protein precursor (AβPP) gene on chromosome 21, the presenilin 1 (PSEN1) gene on chromosome 14, and the presenilin 2 (PSEN2) gene on chromosome 1 [1].”
BackgroundThe effects of human population structure on large genetic association studies
Marchini, J., Cardon, L. R., Phillips, M. S., & Donnelly, P. (2004) · Nature Genetics · doi:10.1038/ng1337 · Cited by 869
Campion, D., Dumanchin, C., Hannequin, D., Dubois, B., Belliard, S., Puel, M., Thomas-Anterion, C., Michon, A., Martin, C., Charbonnier, F., et al. (1999) · The American Journal of Human Genetics · doi:10.1086/302553 · Cited by 785 · cited 1×
“However, the known mutations in these three genes account for less than 1% of all AD cases [2].”
BackgroundSelf-citationThirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses
Bertram, L., & Tanzi, R. E. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2494 · Cited by 747 · cited 1×
“While these observations highlight the importance of genetic factors in the risk for developing AD, at present, only the ε4 allele of the apolipoprotein E (APOE) gene has been unequivocally identified as a major determinant for the non-Mendelian forms of AD [4–6].”
BackgroundSelf-citationClayton, D. G., Walker, N. M., Smyth, D. J., Pask, R., Cooper, J. D., Maier, L. M., Smink, L. J., Lam, A. C., Ovington, N. R., Stevens, H. E., et al. (2005) · Nature Genetics · doi:10.1038/ng1653 · Cited by 526 · cited 1×
“Indeed, this type of difference can lead to spurious associations between diseases and genetic markers [23–26], particularly when low increases in risk are involved [27].”
BackgroundCandidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease
Li, H., Wetten, S., Li, L., St. Jean, P. L., Upmanyu, R., Surh, L., Hosford, D., Barnes, M. R., Briley, J. D., Borrie, M., et al. (2008) · Archives of Neurology · doi:10.1001/archneurol.2007.3 · Cited by 499 · cited 1×
“Despite this contradictory data using affection status as phenotype, three studies, in addition to the original report, showed association between an earlier AAO and homozygosity of the L allele and a marker in the CALHM1 vicinity (11,15,16).”
ResultAge at Onset in Two Common Neurodegenerative Diseases Is Genetically Controlled
Li, Y.-J., Scott, W. K., Hedges, D. J., Zhang, F., Gaskell, P. C., Nance, M. A., Watts, R. L., Hubble, J. P., Koller, W. C., Pahwa, R., et al. (2002) · The American Journal of Human Genetics · doi:10.1086/339815 · Cited by 312 · cited 1×
“Interestingly, several studies have shown that AAO in AD is highly heritable [28,29], and (in addition to the strong association of the ε4 allele with AAO) it has been suggested that genes such as GTS1 or GTS2 may have a specific effects on AAO without necessarily modifying the risk for developing AD [30–32], although…”
BackgroundSelf-citationTranscriptomic and genetic studies identify IL-33 as a candidate gene for Alzheimer's disease
Chapuis, J., Hot, D., Hansmannel, F., Kerdraon, O., Ferreira, S., Hubans, C., Maurage, C. A., Huot, L., Bensemain, F., Laumet, G., et al. (2009) · Molecular Psychiatry · doi:10.1038/mp.2009.10 · Cited by 201 · cited 1×
“Case-control samples were obtained from centers in Belgium (1 study) [12,17], Finland (1 study) [10], France (3 studies) [8,18], Italy (10 studies) [14,17], Spain (4 studies) [15,17], Sweden (1 studies) [10], the UK (1 study) [9], and the USA (3 studies) [8,11,13].”
BackgroundSelf-citationImplication of the Immune System in Alzheimer's Disease: Evidence from Genome-Wide Pathway Analysis
Lambert, J.-C., Grenier-Boley, B., Chouraki, V., Heath, S., Zelenika, D., Fievet, N., Hannequin, D., Pasquier, F., Hanon, O., Brice, A., et al. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-100018 · Cited by 144 · cited 1×
“Comparison of likelihood ratio between a mixed model including only APOE genotype and a mixed model including both APOE and CALHM1 genotypes indicated that addition of the CALHM1 P86L polymorphism was more informative to explain the AAO variability than the APOEε4 allele alone (p = 1 × 10−10).”
BackgroundSelf-citation
Cited by
Alzheimer’s Disease: The Challenge of the Second Century
Holtzman, D. M., Morris, J. C., & Goate, A. M. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002369 · Cited by 1,424
CALHM1 ion channel mediates purinergic neurotransmission of sweet, bitter and umami tastes
Taruno, A., Vingtdeux, V., Ohmoto, M., Ma, Z., Dvoryanchikov, G., Li, A., Adrien, L., Zhao, H., Leung, S., Abernethy, M., et al. (2013) · Nature · doi:10.1038/nature11906 · Cited by 500
Self-citationChami, L., & Checler, F. (2012) · Molecular Neurodegeneration · doi:10.1186/1750-1326-7-52 · Cited by 168
“Currently, the CALHM1 polymorphism is rather considered as a genetic modifier of age at onset in AD [125].”
BackgroundGenome-wide association analysis of age-at-onset in Alzheimer's disease
Kamboh, M. I., Barmada, M. M., Demirci, F. Y., Minster, R. L., Carrasquillo, M. M., Pankratz, V. S., Younkin, S. G., Saykin, A. J., Initiative, T. A. D. N., Sweet, R. A., et al. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.135 · Cited by 100
Self-citationCalhm2 governs astrocytic ATP releasing in the development of depression-like behaviors
Jun, M., Xiaolong, Q., Chaojuan, Y., Ruiyuan, P., Shukun, W., Junbing, W., Li, H., Hong, C., Jinbo, C., Rong, W., et al. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.229 · Cited by 95
Metadata
- Authors
- Lambert, J.-C., Sleegers, K., González-Pérez, A., Ingelsson, M., Beecham, G. W., Hiltunen, M., Combarros, O., Bullido, M. J., Brouwers, N., Bettens, K., Berr, C., Pasquier, F., Richard, F., DeKosky, S. T., Hannequin, D., Haines, J. L., Tognoni, G., Fiévet, N., Dartigues, J.-F., Tzourio, C., Engelborghs, S., Arosio, B., Coto, E., De Deyn, P., Del Zompo, M., Mateo, I., Boada, M., Antunez, C., Lopez-Arrieta, J., Epelbaum, J., Schjeide, B.-M. M., Frank-Garcia, A., Giedraitis, V., Helisalmi, S., Porcellini, E., Pilotto, A., Forti, P., Ferri, R., Delepine, M., Zelenika, D., Lathrop, M., Scarpini, E., Siciliano, G., Solfrizzi, V., Sorbi, S., Spalletta, G., Ravaglia, G., Valdivieso, F., Vepsäläinen, S., Alvarez, V., Bosco, P., Mancuso, M., Panza, F., Nacmias, B., Bossù, P., Hanon, O., Piccardi, P., Annoni, G., Mann, D., Marambaud, P., Seripa, D., Galimberti, D., Tanzi, R. E., Bertram, L., Lendon, C., Lannfelt, L., Licastro, F., Campion, D., Pericak-Vance, M. A., Soininen, H., Van Broeckhoven, C., Alpérovitch, A., Ruiz, A., Kamboh, M. I., & Amouyel, P.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2010-09-28
- Volume
- 22
- Issue
- 1
- Pages
- 247-255
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1657671873
- Cited by
- 56
- References
- 12
- FWCI
- 0.63
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.